chronic arthritis RA Rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Sint Maartenskliniek
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Rheumatoid arthritis (clinical diagnosis of treating rheumatologist, fulfilled at any time point between start of the disease and inclusion, operationalized by DOT diagnosis 101), psoriatic arthritis (clinical diagnosis of treating rheumatologist, operationalized by DOT diagnosis 102 or 202) or spondyloarthritis (clinical diagnosis of treating rheumatologist, operationalized by DOT diagnosis 201) * Treatment with the standard dose of one of the following biologicals: abatacept, adalimumab, certolizumab, etanercept, golimumab or tocilizumab. * Start with a tapering attempt in the context of protocolled tapering in daily clinical practice. * Concomitant treatment with a conventional disease modifying antirheumatic drug (csDMARD) is permitted. * Age * 18 years and mentally competent * Informed consent * Ability to measure the study outcome in the patient (e.g. life expectancy >6 months, no planned relocation far away) * Ability to read and communicate well in Dutch
Exclusion criteria
Exclusion criteria: Not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Successful dose tapering at six months will be used as primary efficacy endpoint. This is operationalised as using a lower than standard dose and remaining in low disease activity or remission at six months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Successful dose tapering at twelve months. | — |
Countries
Netherlands
Outcome results
None listed